MDA-MB-134-VI Xenograft Model Service for Breast Cancer

The MDA-MB-134-VI xenograft model delivers a validated in vivo translational platform designed to evaluate candidate therapies targeting invasive lobular carcinoma (ILC), a distinct and aggressive subtype of ER-alpha-positive breast cancer. Alfa Cytology provides a comprehensive, end-to-end MDA-MB-134-VI xenograft model service, integrating fully authenticated cellular assets with standardized procedural and endocrine-supported protocols to accelerate preclinical oncology drug discovery timelines.

Overview of MDA-MB-134-VI Xenograft Model for Breast Cancer

The MDA-MB-134-VI cell line is a highly specialized and molecularly unique human mammary carcinoma model, clinically recognized as an essential tool for studying invasive lobular carcinoma (ILC). Derived from the pleural effusion of a patient with advanced ductal and lobular breast malignancies, this model is characterized by strong estrogen receptor alpha (ER-alpha) expression and hormone-dependent growth behavior. Notably, MDA-MB-134-VI exhibits a hallmark loss of E-cadherin expression, which accurately recapitulates the diffuse, discohesive growth patterns and high metastatic potential observed in clinical ILC patients. This specific genetic and phenotypic profile makes the MDA-MB-134-VI model an indispensable preclinical test matrix for validating next-generation selective estrogen receptor modulators (SERMs), selective estrogen receptor degraders (SERDs), CDK4/6 inhibitors, and novel combination strategies bypassing endocrine therapy resistance.

When established in vivo as a xenograft in immunocompromised mice, MDA-MB-134-VI cells form solid tumors that faithfully preserve the unique histological architecture and biomarker signatures of human hormone-receptor-positive lobular tumors. Due to the characteristically slow and fastidious growth kinetics profile inherent to true ILC lines, robust tumor propagation in vivo requires highly specialized handling, including precise cell calibration and mandatory supplementation with exogenous estradiol.

Fig 1. VIVA1 subclone and parental MDA-MB-134VI grow in immunocompromised animals following intraductal injection of tumour cells. (Allen V, et al., 2022)

Cell Line Information: MDA-MB-134-VI

The MDA-MB-134-VI cell line maintains a stable, round, and loosely cohesive morphology in vitro and reliably preserves its primary ERα expression and E-cadherin-deficient signatures upon in vivo transplantation.

Our Services

Alfa Cytology provides a fully integrated, turnkey solution for the MDA-MB-134-VI Xenograft Model Service. Our dedication to quality begins with rigorous cell line authentication and mycoplasma testing. We manage every critical step of the preclinical journey—from standardized cell preparation, estradiol supplementation, orthotopic or subcutaneous inoculation, in-life monitoring, to comprehensive endpoint analyses including IHC for ER-alpha and E-cadherin status and PK/PD profiling. Leveraging our expertise in hormone-dependent invasive lobular carcinoma models, we deliver robust data packages tailored to accelerate your drug discovery programs.

Workflow of MDA-MB-134-VI Xenograft Model Construction

Alfa Cytology executes a standardized and strictly regulated workflow to build and validate the MDA-MB-134-VI xenograft model:

• Cell Culture & Quality Control: MDA-MB-134-VI cells are cultivated in cell-bank-certified growth media under optimized ambient parameters. Quality control verification involves mandatory STR profiling and mycoplasma clearance checks to guarantee phenotypic identity and purity before inoculation.
• Host Adaptation & Estrogen Priming: Standardized immunocompromised mice are selected based on study design and pre-implanted with controlled-release estradiol pellets. Animals are acclimated to controlled facility parameters to ensure baseline physiological and hormonal stability.
• Precision Inoculation: A calibrated suspension of high-viability MDA-MB-134-VI cells is prepared and blended with a verified biological matrix carrier to enhance cell survival. The mixture is precisely injected in vivo via subcutaneous or orthotopic routes.
• Longitudinal Growth Tracking: Following model establishment, tumor growth is tracked systematically using high-precision digital calipers under continuous health monitoring. Animal weights and general behavior are routinely recorded to establish dependable growth kinetics.
• Stratification & Dosing: Once the tumors reach a predetermined, statistically optimal volume range, animals are randomized into therapeutic cohorts to balance group parameters perfectly before dosing protocols begin.

Fig 2. MDA-MB-134-VI Xenograft Model Construction Workflow

Case Study - MDA-MB-134-VI Xenograft Model Development

In a recent preclinical trial conducted at Alfa Cytology, the MDA-MB-134-VI xenograft model was successfully utilized to evaluate the efficacy of a novel selective estrogen receptor degrader (SERD) combined with a targeted kinase inhibitor against invasive lobular breast cancer. Under optimized conditions featuring calibrated estradiol supplementation, our technical team achieved highly reproducible tumor engraftment and exceptionally uniform growth curves across all experimental arms, allowing for an unobstructed and definitive assessment of therapeutic efficacy. The in vivo study successfully demonstrated significant, dose-dependent primary tumor growth inhibition in the combination treatment group compared to both the vehicle control and monotherapy arms.

Our Advantages

Choosing the right partner for your hormone-dependent invasive lobular breast cancer research is critical for generating high-quality, reproducible data. Alfa Cytology stands out by offering specialized expertise and high-standard preclinical services:

• Model Authenticity: Fully verified human tumor cell lines with stable, traceable genetic hallmarks.
• Technical Consistency: Optimized inoculation and hormone-supplementation protocols, ensuring uniform tumor growth and minimized variance.
• Multi-Parametric Endpoints: Capacity for advanced readouts, including digital tumor kinetics, target receptor expression analysis, and PK/PD tissue processing.
• Regulatory Compliance: Studies executed by a specialized team adhering strictly to international preclinical research standards.

Contact Us

Are you looking to advance your therapeutic pipeline against hormone-dependent invasive lobular breast cancer using the robust MDA-MB-134-VI xenograft platform? The expert scientific team at Alfa Cytology is ready to build a customized study design that fulfills your strategic research goals. Please contact us today to speak directly with an oncology specialist and request a project-specific consultation and quotation.

For research use only. Not intended for any clinical use.